Detalhe da pesquisa
1.
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Ann Hematol
; 103(1): 117-123, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030891
2.
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Am J Hematol
; 99(6): 1040-1055, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38440831
3.
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
Blood
; 135(3): 191-207, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31750881
4.
Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia.
Cureus
; 14(3): e23618, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35505715
5.
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.
Cancers (Basel)
; 12(8)2020 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32823910